The discussion highlighted advances in allogeneic CAR T-cell therapies, with vispa-cel and CB-011 showing strong efficacy and safety data, targeting underserved patient populations. Upcoming milestones include CB-011 dose expansion data and a pivotal phase III study for vispa-cel.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.